Reports
Sale
Erythema Market Size, Share, Outlook, Report, Forecast: By Type: Erythema Multiforme, Erythema Nodosum, Erythema Ab Igne, Erythema Chronicum Migrans, Erythema Induratum, Erythema Infectiosum, Erythema Marginatum, Others: By Drug Class, By Route of Administration; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Erythema Market Outlook
The erythema market size in the 7 major markets was valued at USD 178.9 million in 2023, driven by rising incidence of cancer across the major markets. The market is expected to grow at a CAGR of 5.8% during the forecast period of 2024-2032, with the values likely to rise from USD 189.3 million in 2024 to USD 297.7 million by 2032.
Erythema: Introduction
Erythema is a wide category of skin condition, characterized by abnormal redness on the skin or mucous membranes. Hyperemia (increased blood) in superficial capillaries is one of the major causes of the condition. It may be an inflammatory response to an infection, massage, drug or medication, acute radiation syndrome, and mercury toxicity, among others. Erythema is of multiple types, with the most common symptoms being circular red bumps, itchiness, blisters, fever, or joint pain.
Erythema Market Analysis
Erythema is a common side effect of chemotherapy; therefore, the rising incidence of cancer cases has directly impacted the erythema market growth in recent years. Consequently, there has been significant emphasis on alleviating the chemotherapy associated symptoms with the help of novel therapeutics. In January 2023, it was revealed that high doses of vitamin D may function as an effective treatment alternative for the condition.
Erythema can be classified into several categories, including erythema multiform, nodosum, and chronicum migraines, among others. The treatment and management differ from condition to condition. Minor diseases are commonly treated with oral antihistamines or topical corticosteroids, whereas severe conditions are treated through systemic steroids.
To tackle recurrent erythema multiform (REM), several trials and developments are going on. As per studies, Azathioprine is one of the many immunosuppressive agents reported to be helpful for unresponsive REM cases to other treatments. With increasing understanding of the human physiology and growing technical advancements, the erythema market value is projected to grow in the forecast period.
Erythema Market Segmentation
Market Breakup by Type
- Erythema Multiforme
- Erythema Nodosum
- Erythema Ab Igne
- Erythema Chronicum Migrans
- Erythema Induratum
- Erythema Infectiosum
- Erythema Marginatum
- Erythema Toxicum
- Erythema Gyratum Repens
- Palmar Erythema
- Erythema Annulare Centrifugum
Market Breakup by Drug Class
- Antibiotics
- Antihistamines
- Analgesics
- NSAIDs
- Corticosteroid
- Antiviral
- Antifungal
- Antibacterial
Market Breakup by Route of Administration
- Oral
- Topical
- Intravenous
- Others
Market Breakup by End User
- Hospital and Clinics
- Ambulatory Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Erythema Market Overview
With a significance on skin health and meeting the high erythema market demand, the United States has experienced critical developments in recent years. The enhancements can be attributed to the presence of key healthcare companies and a well-established infrastructure, contributing extensively to market value.
The rising prevalence of skin conditions drives the market growth in Europe as well. Countries like the United Kingdom, Italy, Germany, and France are some of the key regions offering quality treatments, owing to the presence of prominent research and academic institutions. Mergers and collaborations between key pharmaceutical companies and academic organizations is another important factor for the market size.
The Asia Pacific region, particularly countries like Japan, China, India, and South Korea are also affected by a huge demand. With an affluential traditional medicinal therapy history, the countries are also developing herbal medications for the condition. On the other hand, there have been continuous efforts to improve the healthcare infrastructure for better research and development. Therefore, the region is anticipated to contribute significantly to the erythema market share globally as well.
Erythema Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- GSK plc. (U.S.)
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Astrazeneca
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Abbvie
- Amgen Inc.
- AB Sciences
- Eisai Co., Ltd
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- Valeant Pharmaceuticals International Inc.
- Bausch Health Companies Inc.
- Enzon Pharmaceuticals
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Erythema Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Erythema Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Erythema Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Erythema Epidemiology Forecast (2017-2032)
5.3.1 Germany Erythema Epidemiology Forecast (2017-2032)
5.3.2 France Erythema Epidemiology Forecast (2017-2032)
5.3.3 Italy Erythema Epidemiology Forecast (2017-2032)
5.3.4 Spain Erythema Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Erythema Epidemiology Forecast (2017-2032)
5.4 Japan Erythema Epidemiology Forecast (2017-2032)
6 Erythema Market Overview – 7MM
6.1 Erythema Market Historical Value (2017-2023)
6.2 Erythema Market Forecast Value (2024-2032)
7 Erythema Market Landscape – 7MM
7.1 Erythema: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Erythema Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Drug Class
8 Erythema Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Erythema Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Erythema Market Segmentation – 7MM
11.1 Erythema Market by Type
11.1.1 Market Overview
11.1.2 Erythema Multiforme
11.1.3 Erythema Nodosum
11.1.4 Erythema Ab Igne
11.1.5 Erythema Chronicum Migrans
11.1.6 Erythema Induratum
11.1.7 Erythema Infectiosum
11.1.8 Erythema Marginatum
11.1.9 Erythema Toxicum
11.1.10 Erythema Gyratum Repens
11.1.11 Palmar Erythema
11.1.12 Erythema Annulare Centrifugum
11.2 Erythema Market by Drug Class
11.2.1 Market Overview
11.2.2 Antibiotics
11.2.3 Antihistamines
11.2.4 Analgesics
11.2.5 NSAIDs
11.2.6 Corticosteroid
11.2.7 Antiviral
11.2.8 Antifungal
11.2.9 Antibacterial
11.3 Erythema Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Topical
11.3.4 Intravenous
11.3.5 Others
11.4 Erythema Market by End User
11.4.1 Market Overview
11.4.2 Hospital and Clinics
11.4.3 Ambulatory Clinics
11.4.4 Others
11.5 Erythema Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.4 Japan
12 United States Erythema Market
12.1 Erythema Market Historical Value (2017-2023)
12.2 Erythema Market Forecast Value (2024-2032)
12.2.1 Erythema Market by Disease Type
12.2.2 Erythema Market by Drug Class
13 EU-4 and United Kingdom Erythema Market
13.1 Erythema Market Historical Value (2017-2023)
13.2 Erythema Market Forecast Value (2024-2032)
13.3 Germany Erythema Market Overview
13.3.1 Erythema Market by Disease Type
13.3.2 Erythema Market by Drug Class
13.4 France Erythema Market Overview
13.4.1 Erythema Market by Disease Type
13.4.2 Erythema Market by Drug Class
13.5 Italy Erythema Market Overview
13.5.1 Erythema Market by Disease Type
13.5.2 Erythema Market by Drug Class
13.6 Spain Erythema Market Overview
13.6.1 Erythema Market by Disease Type
13.6.2 Erythema Market by Drug Class
13.7 United Kingdom Erythema Market Overview
13.7.1 Erythema Market by Disease Type
13.7.2 Erythema Market by Drug Class
14 Japan Erythema Market
14.1 Erythema Market Historical Value (2017-2023)
14.2 Erythema Market Forecast Value (2024-2032)
14.2.1 Erythema Market by Disease Type
14.2.2 Erythema Market by Drug Class
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 GSK plc. (U.S.)
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 F. Hoffmann-La Roche Ltd
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Novartis AG
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Astrazeneca
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Pfizer Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Bristol-Myers Squibb Company
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Abbvie
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Amgen Inc.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 AB Sciences
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Eisai Co., Ltd
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Regeneron Pharmaceuticals Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Sanofi S.A.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Valeant Pharmaceuticals International Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Bausch Health Companies Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Enzon Pharmaceuticals
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Erythema Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 178.9 million in 2023, driven by growing incidence of cancer across the globe.
The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032, likely to reach a market value of USD 297.7 million by 2032.
The market demand is driven by the increasing drug developments and trials to offer better patient outcomes.
The market trend involves the increasing focus on developing personalised medicine for patients. High dosage of vitamin D is being administered to patients to minimise the chemotherapy associated side effects.
Based on types, the market is divided into erythema multiforme, nodosum, ab igne, chronicum migrans, induratum, infectiosum, marginatum, toxicum, gyratum repens, palmar erythema and annulare centrifugum.
Common mechanism of action includes antibiotics, antihistamines, analgesics, NSAIDs, corticosteroid, antiviral, antifungal and antibacterial.
Major end users include hospitals, clinics, and ambulatory clinics, among others.
The route of administration can be oral, topical, intravenous among others.
The major regions of the market include the United States, Japan, EU-4, which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are GSK plc. (U.S.), F. Hoffmann-La Roche Ltd., Novartis AG, Astrazeneca, Pfizer Inc., Bristol-Myers Squibb Company, Sanofi, Amgen Inc., AB Sciences, Eisai Co., Ltd., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Bausch Health Companies Inc., and Enzon Pharmaceuticals.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER